The Phase III DIAMOND trial met both its primary and secondary endpoints of reducing tics in both children and adult patients ...

In the Phase III trial, 41.9% of pediatric Tourette syndrome patients relapsed after ecopipam treatment, as compared with ...

Ecopipam showed statistical significance in treating Tourette syndrome versus a placebo for both its primary efficacy ...

Emalex Biosciences’ dopamine blocker led to fewer patients with Tourette syndrome relapsing in a phase 3 trial, setting the ...

Emalex Biosciences met primary and secondary endpoints in its Phase 3 registrational trial of ecopipam for patients with ...

CDC staff received an email this week telling them to avoid using more than a dozen terms or words -- including "health ...

Emalex Biosciences said its daily oral tablet helped reduce relapses for children and adults with Tourette syndrome in a ...

Cision, a global leader in media intelligence and communications solutions, in partnership with PRWeek, today announced the ...

Sharp Electronics Corporation (SEC) is pleased to announce that Sharp has been named to the 2025 Fortune World's Most Admired ...

At the moment, attention is focused on candidates like Emalex Biosciences' ecopipam and Noema Pharma's gemlapodect, both in midstage clinical testing. An extraordinary meeting of shareholders is ...

Ligand Pharmaceuticals (Nasdaq: LGND) has entered into a royalty financing agreement with Castle Creek Biosciences, providing ...